ArticleAmerican journal of translational research2026
Effect of Huaier Granules combined with transarterial chemoembolization on recurrence and survival in postoperative hepatocellular carcinoma patients with microvascular invasion.
Article in American journal of translational research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo evaluate whether Huaier Granules combined with transcatheter arterial chemoembolization (TACE) reduces recurrence and improves survival in patients with microvascular invasion (MVI)-positive primary hepatocellular carcinoma (HCC) after resection.
methodsA single-center retrospective study enrolled 266 patients (2019-2021), who were divided into the Huaier Granules + TACE group (Observation Group) (n=137) and the TACE alone group (Control Group) (n=129). Key outcomes included recurrence-free survival (RFS), overall survival (OS), objective response rate (ORR), liver function, adverse events (AEs), and health-related quality of life (HRQoL) assessed by the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Hepatocellular Carcinoma 18-question module. Survival was analyzed using the Kaplan-Meier method; Cox regression and receiver operating characteristic (ROC) analysis were employed to explore prognostic factors and evaluate discrimination.
resultsCompared with TACE alone, the combination group had a higher ORR (55.47% vs 38.76%, P<0.005), lower 1-/2-/3-year recurrence rates (16.79%/44.53%/78.10% vs 26.36%/53.48%/89.15%, P<0.05), and longer RFS and OS (both P<0.05). The combination group exhibited more significant improvements in alanine aminotransferase (ALT), aspartate aminotransferase (AST), total bilirubin (TBil), and albumin (ALB) (all P<0.05), with a comparable AE rate (P>0.05) and better 3-month HRQoL (all P<0.05). Multivariable analysis identified Tumor-Node-Metastasis (TNM) stage, post-treatment AST, and treatment modality as independent predictors of 3-year mortality, with modest area under the curve values (0.572-0.699).
conclusionHuaier Granules combined with TACE was associated with reduced recurrence, prolonged survival, favorable safety, and better short-term HRQoL in this cohort. These findings require cautious interpretation and prospective validation due to the study's limitations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.